Comment
doi: 10.1200/JCO.2017.77.0891.
Epub 2018 Mar 8.
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer
Affiliations
- PMID: 29517943
- DOI: 10.1200/JCO.2017.77.0891
Item in Clipboard
Comment
Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer
J Clin Oncol.
.
No abstract available
Comment on
-
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5. J Clin Oncol. 2018. PMID: 29401002 Free PMC article. Clinical Trial.
Similar articles
-
The PI3Kα Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors.Cancer Discov. 2018 Apr;8(4):OF7. doi: 10.1158/2159-8290.CD-RW2018-027. Epub 2018 Feb 16. Cancer Discov. 2018. PMID: 29453241
-
Breaking up is hard to do: PI3K isoforms on the rebound.Cancer Cell. 2015 Jan 12;27(1):5-7. doi: 10.1016/j.ccell.2014.12.003. Cancer Cell. 2015. PMID: 25584888
-
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.Bioorg Med Chem Lett. 2013 May 1;23(9):2606-13. doi: 10.1016/j.bmcl.2013.02.102. Epub 2013 Mar 7. Bioorg Med Chem Lett. 2013. PMID: 23540645
-
Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer.Int J Mol Sci. 2018 Dec 7;19(12):3931. doi: 10.3390/ijms19123931. Int J Mol Sci. 2018. PMID: 30544563 Free PMC article. Review.
-
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14. Acta Pharmacol Sin. 2015. PMID: 26364801 Free PMC article. Review.
Cited by
-
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.Clin Cancer Res. 2020 Nov 15;26(22):5903-5913. doi: 10.1158/1078-0432.CCR-20-2000. Epub 2020 Sep 10. Clin Cancer Res. 2020. PMID: 32913135 Free PMC article.
-
PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.Sci Rep. 2023 Mar 18;13(1):4467. doi: 10.1038/s41598-023-31593-w. Sci Rep. 2023. PMID: 36934165 Free PMC article.
-
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.Drug Saf. 2019 Feb;42(2):247-262. doi: 10.1007/s40264-018-0778-4. Drug Saf. 2019. PMID: 30649751 Review.
-
The role of the PIK3CA gene in the development and aging of the brain.Sci Rep. 2021 Jan 11;11(1):291. doi: 10.1038/s41598-020-79416-6. Sci Rep. 2021. PMID: 33431926 Free PMC article.
-
Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester.J Med Chem. 2018 Dec 13;61(23):10463-10472. doi: 10.1021/acs.jmedchem.8b00975. Epub 2018 Nov 28. J Med Chem. 2018. PMID: 30380865 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
